Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon

Katherine J. Torres, Carlos E. Castrillon, Eli L. Moss, Mayuko Saito, Roy Tenorio, Douglas M. Molina, Huw Davies, Daniel E. Neafsey, Philip Felgner, Joseph M. Vinetz, Dionicia Gamboa

Research output: Contribution to journalArticle

Abstract

Background Persons with blood-stage Plasmodium falciparum parasitemia in the absence of symptoms are considered to be clinically immune. We hypothesized that asymptomatic subjects with P. falciparum parasitemia would differentially recognize a subset of P. falciparum proteins on a genomic scale. Methods and Findings. Compared with symptomatic subjects, sera from clinically immune, asymptomatically infected individuals differentially recognized 51 P. falciparum proteins, including the established vaccine candidate PfMSP1. Novel, hitherto unstudied hypothetical proteins and other proteins not previously recognized as potential vaccine candidates were also differentially recognized. Genes encoding the proteins differentially recognized by the Peruvian clinically immune individuals exhibited a significant enrichment of nonsynonymous nucleotide variation, an observation consistent with these genes undergoing immune selection. Conclusions. A limited set of P. falciparum protein antigens was associated with the development of naturally acquired clinical immunity in the low-transmission setting of the Peruvian Amazon. These results imply that, even in a low-transmission setting, an asexual blood-stage vaccine designed to reduce clinical malaria symptoms will likely need to contain large numbers of often-polymorphic proteins, a finding at odds with many current efforts in the design of vaccines against asexual blood-stage P. falciparum.

Original languageEnglish (US)
Pages (from-to)1342-1351
Number of pages10
JournalJournal of Infectious Diseases
Volume211
Issue number8
DOIs
StatePublished - Apr 15 2015
Externally publishedYes

Fingerprint

Plasmodium falciparum
Immunity
Genome
Vaccines
Proteins
Parasitemia
Adaptive Immunity
Malaria
Immune Sera
Nucleotides
Observation
Antigens
Genes

Keywords

  • geographic medicine
  • immunology
  • malaria
  • systems biology

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Torres, K. J., Castrillon, C. E., Moss, E. L., Saito, M., Tenorio, R., Molina, D. M., ... Gamboa, D. (2015). Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon. Journal of Infectious Diseases, 211(8), 1342-1351. https://doi.org/10.1093/infdis/jiu614

Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon. / Torres, Katherine J.; Castrillon, Carlos E.; Moss, Eli L.; Saito, Mayuko; Tenorio, Roy; Molina, Douglas M.; Davies, Huw; Neafsey, Daniel E.; Felgner, Philip; Vinetz, Joseph M.; Gamboa, Dionicia.

In: Journal of Infectious Diseases, Vol. 211, No. 8, 15.04.2015, p. 1342-1351.

Research output: Contribution to journalArticle

Torres, KJ, Castrillon, CE, Moss, EL, Saito, M, Tenorio, R, Molina, DM, Davies, H, Neafsey, DE, Felgner, P, Vinetz, JM & Gamboa, D 2015, 'Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon', Journal of Infectious Diseases, vol. 211, no. 8, pp. 1342-1351. https://doi.org/10.1093/infdis/jiu614
Torres, Katherine J. ; Castrillon, Carlos E. ; Moss, Eli L. ; Saito, Mayuko ; Tenorio, Roy ; Molina, Douglas M. ; Davies, Huw ; Neafsey, Daniel E. ; Felgner, Philip ; Vinetz, Joseph M. ; Gamboa, Dionicia. / Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon. In: Journal of Infectious Diseases. 2015 ; Vol. 211, No. 8. pp. 1342-1351.
@article{5ed2c85072854bc286ca3b656e404642,
title = "Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon",
abstract = "Background Persons with blood-stage Plasmodium falciparum parasitemia in the absence of symptoms are considered to be clinically immune. We hypothesized that asymptomatic subjects with P. falciparum parasitemia would differentially recognize a subset of P. falciparum proteins on a genomic scale. Methods and Findings. Compared with symptomatic subjects, sera from clinically immune, asymptomatically infected individuals differentially recognized 51 P. falciparum proteins, including the established vaccine candidate PfMSP1. Novel, hitherto unstudied hypothetical proteins and other proteins not previously recognized as potential vaccine candidates were also differentially recognized. Genes encoding the proteins differentially recognized by the Peruvian clinically immune individuals exhibited a significant enrichment of nonsynonymous nucleotide variation, an observation consistent with these genes undergoing immune selection. Conclusions. A limited set of P. falciparum protein antigens was associated with the development of naturally acquired clinical immunity in the low-transmission setting of the Peruvian Amazon. These results imply that, even in a low-transmission setting, an asexual blood-stage vaccine designed to reduce clinical malaria symptoms will likely need to contain large numbers of often-polymorphic proteins, a finding at odds with many current efforts in the design of vaccines against asexual blood-stage P. falciparum.",
keywords = "geographic medicine, immunology, malaria, systems biology",
author = "Torres, {Katherine J.} and Castrillon, {Carlos E.} and Moss, {Eli L.} and Mayuko Saito and Roy Tenorio and Molina, {Douglas M.} and Huw Davies and Neafsey, {Daniel E.} and Philip Felgner and Vinetz, {Joseph M.} and Dionicia Gamboa",
year = "2015",
month = "4",
day = "15",
doi = "10.1093/infdis/jiu614",
language = "English (US)",
volume = "211",
pages = "1342--1351",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon

AU - Torres, Katherine J.

AU - Castrillon, Carlos E.

AU - Moss, Eli L.

AU - Saito, Mayuko

AU - Tenorio, Roy

AU - Molina, Douglas M.

AU - Davies, Huw

AU - Neafsey, Daniel E.

AU - Felgner, Philip

AU - Vinetz, Joseph M.

AU - Gamboa, Dionicia

PY - 2015/4/15

Y1 - 2015/4/15

N2 - Background Persons with blood-stage Plasmodium falciparum parasitemia in the absence of symptoms are considered to be clinically immune. We hypothesized that asymptomatic subjects with P. falciparum parasitemia would differentially recognize a subset of P. falciparum proteins on a genomic scale. Methods and Findings. Compared with symptomatic subjects, sera from clinically immune, asymptomatically infected individuals differentially recognized 51 P. falciparum proteins, including the established vaccine candidate PfMSP1. Novel, hitherto unstudied hypothetical proteins and other proteins not previously recognized as potential vaccine candidates were also differentially recognized. Genes encoding the proteins differentially recognized by the Peruvian clinically immune individuals exhibited a significant enrichment of nonsynonymous nucleotide variation, an observation consistent with these genes undergoing immune selection. Conclusions. A limited set of P. falciparum protein antigens was associated with the development of naturally acquired clinical immunity in the low-transmission setting of the Peruvian Amazon. These results imply that, even in a low-transmission setting, an asexual blood-stage vaccine designed to reduce clinical malaria symptoms will likely need to contain large numbers of often-polymorphic proteins, a finding at odds with many current efforts in the design of vaccines against asexual blood-stage P. falciparum.

AB - Background Persons with blood-stage Plasmodium falciparum parasitemia in the absence of symptoms are considered to be clinically immune. We hypothesized that asymptomatic subjects with P. falciparum parasitemia would differentially recognize a subset of P. falciparum proteins on a genomic scale. Methods and Findings. Compared with symptomatic subjects, sera from clinically immune, asymptomatically infected individuals differentially recognized 51 P. falciparum proteins, including the established vaccine candidate PfMSP1. Novel, hitherto unstudied hypothetical proteins and other proteins not previously recognized as potential vaccine candidates were also differentially recognized. Genes encoding the proteins differentially recognized by the Peruvian clinically immune individuals exhibited a significant enrichment of nonsynonymous nucleotide variation, an observation consistent with these genes undergoing immune selection. Conclusions. A limited set of P. falciparum protein antigens was associated with the development of naturally acquired clinical immunity in the low-transmission setting of the Peruvian Amazon. These results imply that, even in a low-transmission setting, an asexual blood-stage vaccine designed to reduce clinical malaria symptoms will likely need to contain large numbers of often-polymorphic proteins, a finding at odds with many current efforts in the design of vaccines against asexual blood-stage P. falciparum.

KW - geographic medicine

KW - immunology

KW - malaria

KW - systems biology

UR - http://www.scopus.com/inward/record.url?scp=84926639432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926639432&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu614

DO - 10.1093/infdis/jiu614

M3 - Article

VL - 211

SP - 1342

EP - 1351

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -